Manlangit, Baby Boy .

HRN: 26-44-82  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/06/2025
AMPICILLIN 1GM (VIAL)
01/06/2025
01/13/2025
IV
160mg
Q12h
PSNB
Waiting Final Action 
01/06/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/06/2025
01/13/2025
IV
48mg
Q24h
PSNB
Waiting Final Action 
01/06/2025
CEFOTAXIME 500MG (VIAL)
01/06/2025
01/13/2025
IV
160mg
Q12h
PSNB
Waiting Final Action 
01/11/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/11/2025
01/18/2025
IV
300mg
Q12
UTI, PSNB
Waiting Final Action 
01/15/2025
MUPIROCIN 2%, 15G (TUBE)
01/15/2025
01/22/2025
SKIN
0.5mg
BID
Phlebitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: